{"altmetric_id":3680912,"counts":{"readers":{"mendeley":23,"citeulike":0,"connotea":0},"total":{"posts_count":1},"wikipedia":{"unique_users_count":1,"unique_users":["en:33071344"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa5063cf058f6100030ec","authors":["Mohd. Islam","Magdy Iskander"],"doi":"10.2174\/1389557043402946","endpage":"1104","first_seen_on":"2015-02-15T21:10:03+00:00","issns":["13895575"],"issue":"10","journal":"Mini Reviews in Medicinal Chemistry","last_mentioned_on":1385145846,"links":["http:\/\/dx.doi.org\/10.2174\/1389557043402946"],"pubdate":"2004-12-01T00:00:00+00:00","publisher_subjects":[{"name":"Medicinal And Biomolecular Chemistry","scheme":"era"},{"name":"Pharmacology And Pharmaceutical Sciences","scheme":"era"}],"scopus_subjects":["Life Sciences","Pharmacology, Toxicology and Pharmaceutics"],"startpage":"1077","title":"Microtubulin Binding Sites as Target for Developing Anticancer Agents","type":"article","volume":"4","mendeley_url":"http:\/\/www.mendeley.com\/research\/microtubulin-binding-sites-target-developing-anticancer-agents"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":3627884,"mean":4.9451200333677,"rank":817400,"this_scored_higher_than_pct":63,"this_scored_higher_than":2287272,"rank_type":"exact","sample_size":3627884,"percentile":63},"similar_age_3m":{"total_number_of_other_articles":97297,"mean":8.1126431096861,"rank":25205,"this_scored_higher_than_pct":72,"this_scored_higher_than":71009,"rank_type":"exact","sample_size":97297,"percentile":72},"this_journal":{"total_number_of_other_articles":208,"mean":2.215845410628,"rank":22,"this_scored_higher_than_pct":55,"this_scored_higher_than":116,"rank_type":"exact","sample_size":208,"percentile":55},"similar_age_this_journal_3m":{"total_number_of_other_articles":20,"mean":1.0263157894737,"rank":1,"this_scored_higher_than_pct":95,"this_scored_higher_than":19,"rank_type":"exact","sample_size":20,"percentile":95}}},"demographics":{"users":{"mendeley":{"by_status":{"Researcher":7,"Student  > Doctoral Student":3,"Student  > Ph. D. Student":4,"Student  > Master":4,"Other":1,"Student  > Bachelor":2,"Lecturer > Senior Lecturer":2},"by_discipline":{"Engineering":1,"Medicine and Dentistry":1,"Chemistry":12,"Immunology and Microbiology":1,"Agricultural and Biological Sciences":6,"Biochemistry, Genetics and Molecular Biology":1,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"mendeley":{"CO":1,"BR":1,"MX":2}}},"posts":{"wikipedia":[{"title":"Discovery and development of tubulin inhibitors","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=582850755#altmetric_citation_3","license":"public","citation_ids":[3680912,3680913],"posted_on":"2013-11-22T18:44:06+00:00","summary":"Tubulin inhibitors are drugs that interfere directly with the tubulin system, which is in contrast to those drugs acting on DNA for cancer chemotherapy.","page_url":"http:\/\/en.wikipedia.org\/?curid=33071344","wiki_lang":"en","author":{"name":"Chris Capoccia","url":"http:\/\/en.wikipedia.org\/wiki\/User:Chris Capoccia"}}]}}